You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY21 is not expected to be complete until September, 2022.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Risperidone Subcutaneous Implant

    SBC: Delpor, Inc            Topic: 101

    The objective of the proposed study is to develop a subcutaneous implant of risperidone that provides consistent therapeutic blood levels of the drug for 6 months after a single administration. The device is implanted during a simple, 10-minute, in-office procedure with local anesthetic. The benefits of the product include improved medication adherence, fewer relapses, ability to withdraw the medi ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Developing and Evaluating In-Home Supportive Technology for Dementia Caregivers

    SBC: PEOPLE POWER COMPANY            Topic: NIA

    AbstractCaring for a loved one with Alzheimer’s disease, frontotemporal dementia, or another neurodegenerative disease is a highly meaningful part of family life. However, the associated burden and strain can have adverse effects on caregivers including mental and physical health problems, reduced well-being, and increased mortality. These effects, in turn, can compromise care quality and shorte ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Highly accurate small-RNA sequencing of single cells (RealSeq-SC)

    SBC: REALSEQ BIOSCIENCES, INC.            Topic: 172

    Abstract The goal of this grant application is to develop the first commercially available library preparation kit for profiling small RNAs from single cells using NGS methods. Single-cell analyses of mRNA have allowed the identification of crucial differences between cells that were otherwise considered identical. These findings have shown that there is intrinsic “noise” in the regulation of ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Lead Optimization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease

    SBC: Vivreon Biosciences, LLC            Topic: NIA

    Vivreon Biosciences, LLC7558 Trade St.San Diego, CA 92121 vivreonbiosciences@gmail.com Vivreon Biosciences – NIA SBIR # PA-18-187 Project Summary Vivreon Biosciences is pleased to apply for NIA SBIR Solicitation #PA-18-187. Vivreon Biosciences is an innovative life sciences company that is developing a series of novel small molecule, Ca2+ channel inhibitors for the treatment of Alzheimerandapos; ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Device to control circadian-effective light in Alzheimer's disease environments

    SBC: ERIK PAGE & ASSOCIATES, INC.            Topic: NIA

    Project Summary This proposed project will develop and field-test a device that accurately monitors and controls the circadian stimulus (CS) for Alzheimer disease (AD) and Alzheimer-disease-related dementia (ADRD) patients in nursing homes. Human biology has evolved to have two distinct optical systems: the visual system, by which we see and process images, and the circadian system, which regulate ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  6. PIKFYVE antagonism as a therapy for C9ORF72-ALS/FTD

    SBC: AcuraStem Inc.            Topic: 101

    Optimization and validation of PIKFYVE antagonism as a therapy for C9ORF72-ALS/FTD Project Summary / Abstract The C9ORF72 repeat expansion mutation is the most common cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), accounting for over 50% of ALS cases in northern Europe and 10% of cases worldwide, making it a critical target for therapeutic intervention. Using patie ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Development of a Field-Deployable Device to Rapidly Measure Blood Cyanide Levels

    SBC: DIAGNOSTIC CONSULTING NETWORK, INC            Topic: NINDS

    PROJECT SUMMARY The objective of this proposal is to complete the development and verify the performance of a field-deployable, fully integrated sensor for the rapid and early diagnosis of cyanide poisoning in whole blood. Cyanide is an extremely potent and rapid acting poison. It can be inhaled or absorbed across the skin as cyanide gas or ingested as cyanide salt, and has multiple mechanisms of ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  8. A scalable system for high-throughput and longitudinal electrophysiology in rodent brain research

    SBC: SPIKEGADGETS, INC.            Topic: 101

    Psychiatric disorders give rise to aberrant patterns of activity within the complex neural circuits of our brains. Yet, the exact nature of these abnormal patterns is often unknown to developers of new treatments. The goal of this project is to enable circuit-oriented research of neuropsychiatric diseases using rodent disease models. The long-term objective is to catalyze the discovery of new ther ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Lead optimization and development of novel targeted small molecule therapeutics for Alzheimers disease

    SBC: Epigen Biosciences, Inc.            Topic: NIA

    Alzheimerandapos;s disease (AD) is a devastating disease, with an insidious onset and relentless progress. It produces distressing changes in memory, thought, perception, and often behavior. These changes increasingly impact the patientandapos;s daily life, reducing functional independence, until ultimately, the patients are entirely dependent on others. AD is a progressive disease, where the neur ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Tailoring the Hydroxyl Radical Foot-Printing Approach to Provide a Solution for the Higher Order Structural Analysis Needs of the Biopharmaceutical Industry

    SBC: GENNEXT TECHNOLOGIES, INC.            Topic: 400

    The GenNext Phase II SBIR submssion entitled “Tailoring the Hydroxy Radical Foot-Printing Approach to Provide a Solution for the Higher Order Structural Analysis Needs of the Biopharmaceutical Industry” is responsive to the ackowledged need for new and improved tools for higher order structural analysis (HOS) of biopharmaceuticals. Unlike conventional drugs, biopharmaceuticals are complex, het ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government